Facible Biodiagnostics | Clémentine Gibard Bohachek, CSO


Clementine Gibard Bohachek

Clementine Gibard Bohachek

CSO, Facible BioDiagnostics
Steven Burden

Steven Burden

CEO, Facible BioDiagnostics
Facible Biodiagnostics is leading the diagnostic testing revolution through our mission to provide hospital-grade diagnostic tests to everyone, everywhere.


Clementine Gibard  0:05  

Hi. So my name is actually Clementine. And so I'm sure my accent gave it away already. I am not from the States. I was actually born and raised in the French Alps where I studied chemistry. And I always dream of being a world class chemist. So I decided to come to the States. And I got to fill a position at the Scripps Research Institutes. So I was really living my dream there working with those very famous and amazing scientists and and then my career kind of took a shift. My cursor maker shifted, when my very sexy American boyfriend kneeled down at the airport next to the trash can and proposed. I was told by my friends, my colleagues, my PI, you can't move to Boise, Idaho, like it's just a death sentence for your carrier, but I think they were wrong. So I'm really honored to be here today. And to tell you about possible and our revolutionary technology, Q-Laad. Our mission is really to like provide this hospital grade diagnostic in a point of care setting for everyone. And sorry. And I think it's pretty important for everyone to have access to this very high quality diagnostic. It was a lady during this current pandemic, for example, all this technology that we are currently using, and I'm saying currently, I'm talking about technology that have been used for the past, what 25, maybe 30 years. But those techniques, they have limitation. For example, qPCR qPCR, is the gold standards, it's incredibly incredible, and it is very, very, very sensitive, sometimes in salmon stands a little bit too sensitive. But the problem here is that PCR really belongs in the lab, it's really hard to adapt this technology to a point of care setting. Then you have isothermal amplification, a little bit of an easier workflow for sure. But once again, it's fully aware when it's can be using the point of care antigenic test, easy to use right you can do that at home they are pretty basic. But in that case, I'm not so sensitive anyone for transit. So now please, please let me introduce you to Q-Laad provide the diagnostic industry without sacrificing speed, ease of use, or accuracy. The chemistry behind cue lads can provide you with results about five minutes typically. And chilla is really has easy to use as it is accurate. So I'm going to tell you a little bit more how it works. So you can really picture colada has a as a DNA transistor or maybe like an intelligent oligonucleotide, it has to bind in pockets and the logic gets in the middle. And so the first pocket will be able to recognize and to bind specifically to our desire targets. And that will send a signal to the second binding pockets and induce a conformational change. Now, the second pocket can bind to a reported molecule and your case this reported molecule can emit fluorescence. And so really, this introduction of the N gate 12 technology provides us with a very high specificity. And that was proven during the characterization of our Saska. To assay. We actually submitted it to the FDA under the EUA. And we are currently working together with them in order to get authorized and out in the markets or test has proven to show about not about exact 97 person sensitivity. And that was done over the full range of PCR and specificity was 100 persons. In top of that the limit of detection of our assay is comparable with qPCR and is as good as the best Eliza assay. We also have been working in a program in robotics that has been started by the NIH. And they have been supporting us and vetting all technology since 2020. So now we have proven our technology. We are evolving it throughout the most exciting tests. So for example, right now we are walking in the respiratory panel. And what's really revolutionary with this six pathogen panel is that it will be in a point of care setting. So just think about it. In five minutes, you will be able to tell which bug as me as make your kid sick for example. And what really matter here is that you will have access to this hospital grade diagnostic without having to go to the hospital animal, which is great when you have kids.A second integration will be the addition of 15 OTC pathogen to our assay, those one will be a little bit more rare. And again, what I really want to do is to bring this hospital grade diagnostic to everyone that mean that we want this analyzer to be available at your pharmacies or clinics or even at your doctor office. Another evolution will be what we call stratification. So what that means is that we are going to develop or probes to bind to a very specific part of the pathogen, because then we really want to tell from which train it is. So for example, instead of just being diagnosed with the way of B, we'll be able to tell you, it's h one n one. And that's really matter, because we're going to be able to generate this enormous amount of data. And that will obviously have a very high financial interest. But what's really matter is that it will be used in research to make therapy vaccine or even mutation drip survey, much better. Just think about it for flu, for example, like if we can map and picture which strain is infecting which part of the states or even of the word, we'll be able to feed that in the new model, and able to generate a much better vaccine than what is currently available. There is over 400 million people every year that get diagnosed with one of the six respiratory pathogens, that means that there is about four to five times more people that actually take the test, right. So the jig in the market is just gigantic. But here, what I wanted to tell you is that there was just no reason why or technology should be applied only to human health. It could be applied to plan diagnostic, human health, environmental, diagnostic, anything. And if you combine all of those verticals together, it gets a market as big as about $400 billion a year. So in order to get our technology available for everyone, we are raising money. And we are utilizing this regulation, a plus that you probably have heard a few times today and the day before. And what it really allowed us to do is to sell those private security, private security in a public offering. And that not only to accredited and institutional investors, but also to retail investors. And there was really two reason why we chose this strategy for all series a fundraising. And the first one is that we just really want to raise this money rapidly because what matters to us is to get our product out of the market as soon as we can. And the second reason is, I think we really liked the idea that anybody in vessels or not and from the US or from France, or from anywhere can actually be part of our diagnostic revolution. And seriously, don't you think that this will look pretty cool next to or maybe instead of your Alexa Monday in your own house? Thank you so much.

LSI Europe '23 is filling fast. Secure your spot today to join Medtech leaders in Barcelona.


Share this video

Companies We Work With